Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019-Reference-Cited by-同舟云学术

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Published:2021-04-13 Issue:8 Volume:17 Page:2482-2487
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Patterson Brandon J.¹^ORCID,Chen Chi-Chang²^ORCID,McGuiness Catherine B.²^ORCID,Glasser Lisa I.¹^ORCID,Sun Kainan²^ORCID,Buck Philip O.¹^ORCID

Affiliation:

1. US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission]

2. IQVIA, Pennsylvania, PA, USA

Funder

GlaxoSmithKline Biologicals SA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1879579

Reference32 articles.

1. Varicella zoster virus infection

2. Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease, and Latency

3. Herpes Zoster

4. Analysis of Vascular Event Risk After Herpes Zoster From 2007 to 2014 US Insurance Claims Data

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge, Attitudes, and Practices Regarding Herpes Zoster Vaccination Among Specialists;Population Health Management;2024-08-01

2. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence;Human Vaccines & Immunotherapeutics;2023-11-15

3. Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate;Vaccines;2023-11-02

4. Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study;JMIR Public Health and Surveillance;2023-10-04

5. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50–59 years;Vaccine;2023-08